| 货号 | 16299-50mg |
| 描述 | Phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (Item No. 13346) (mTOR) constitutively signal and drive cell survival and proliferation in many forms of cancer.1,2 XL765 is a dual inhibitor of both PI3K and mTOR, completely blocking phosphorylation of substrates at 8-16 µM.3,4 Similarly, XL765 is cytotoxic to glioblastoma multiforme (GBM) xenografts in vitro, with half maximal inhibition occurring at 3.7-7.7 µM.4 XL765 is orally bioavailable and passes the blood-brain barrier, reducing the growth of intracranial GBM xenografts in mice.4 This inhibitor is effective alone or in combination therapy with other compounds in various types of cancer.3,4,5 |
| 别名 | SAR245409;Voxtalisib; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Benjamin, D.,Colombi, M.,Moroni, C., et al. Rapamycin passes the torch: A new generation of mTOR inhibitors. Nature Reviews.Drug Discovery 10(11), 868-880 (2011). 2.Schenone, S.,Brullo, C.,Musumeci, F., et al. ATP-competitive inhibitors of mTOR: An update. Current Medicinal Chemistry 18, 2995-3014 (2011). 3.Molckovsky, A. and Siu, L.L. First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American society of clinical oncology meeting. J.Hematol.Oncol. 1, 1-9 (2008). 4.Prasad, G.,Sottero, T.,Yang, X., et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro.Oncol. 13(4), 384-392 (2011). 5.Ghadimi, M.P.,Lopez, G.,Torres, K.E., et al. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Molecular Cancer Therapeutics 11(8), 1758-1769 (2012). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥95% |
| 计算分子量 | 599.7 |
| 分子式 | C31H29N5O6S |
| CAS号 | 1349796-36-6 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |